NO-SPA, SOOTHING OR REMOVING SPASMS, SANOFI AVENTIS, TABLETS X24, 40mg

Ingredients: 1 tablet contains: drotaverine hydrochloride 40 mg.

Other ingredients: magnesium stearate, talc, valium, corn starch, lactose monohydrate.

Mode of action: NO-SPA - antispasmodic.

Drotaverine is an isoquinoline derivative that has an antispasmodic effect on smooth muscle by inhibiting the enzyme phosphodiesterase 4 (PDE 4). PDE 4 enzyme inhibition results in increased concentration camp, which inactivates myosin light chain kinase (MLCK), which in turn leads to smooth muscle relaxation. Drotaverine inhibits PDE 4 enzyme in vitro without inhibiting PDE isoenzymes PDE 3 and 5. Obviously, PDE IV is functionally very important for reducing smooth muscle contractility, so selective PDE 4 inhibitors may be useful in the treatment of hyperkinetic disorders and diseases. associated with spasms of the gastrointestinal tract.

The enzyme hydrolyzes with AMP in smooth muscle and vascular cells mainly isoenzyme PDE 3, which explains the high efficiency of drotaverine, expressed in the lack of antispasmodic activity on the cardiovascular system.

The drug is effective in spasms of smooth muscles, as well as nerve and muscle etiology. Regardless of the type of autonomic innervation, drotaverine acts on the smooth muscles of the gastrointestinal tract, bile ducts and urogenital and circulatory systems.

Thanks to the vasodilating effect of No-spa, it improves blood circulation.

Smooth muscle spasms associated with biliary tract diseases: cholecystolithiasis, cholecystitis, cholangitis, papillitis.

Spasms of the smooth muscles of the urinary system: nephrolithiasis, pyelitis, cystitis, urinary tenesmus.

As concomitant therapy: in spasm of the smooth muscles of the gastrointestinal tract - gastric and duodenal ulcers, gastritis, gastric cardia and pyloric spasm, enteritis, colitis, spastic constipation, irritable bowel syndrome, flatulence, meteorism, headache, headache.

Contraindications: Do not take in severe renal or hepatic impairment. Severe heart failure (low heart rate syndrome). Children under one year of age (do not take this product. In case of hypersensitivity to drotaverine or to the drug. In case of galactosemia syndrome or impaired glucose absorption.

Precautions: Do not take in case of arterial hypotension. Pregnancy and lactation. Due to the lack of clinical data during lactation is not recommended.

Dosage and method of administration: For adults, the usual average daily dose is 120-240 mg (2-3 hours). For children 1-6 years - 40-120 mg 2-3 times, over 6 years - 80-200 mg in 2-5 doses.

Side effects: From the digestive system: rarely - nausea, constipation. On the nervous system: rarely - headache, dizziness, and insomnia. For the cardiovascular system: rarely - palpitations, very rarely - hypotension.

Warning: The tablets contain 52 mg of lactose. This can cause gastrointestinal complaints in patients suffering from lactose intolerance. This form is not acceptable for patients with lactose intolerance, galactosemia or impaired glucose absorption.

Effects on ability to drive and use machines: when administered in therapeutic doses, drotaverine does not affect the ability to drive and perform work, requires special care.

Drug interactions: Caution should be exercised when used in combination with levodopa, as the antiparkinsonian effect of the latter decreases and an increase in tremor and hardness is observed.

Storage conditions: Store in a dark place at 15-25 ° C.

Shelf life: 3 years.